Lv3
380 积分 2021-02-24 加入
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
5小时前
待确认
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer
5小时前
已完结
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
5小时前
已完结
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
5小时前
已完结
Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma
5小时前
已完结
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma
6小时前
已完结
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma
6小时前
已完结
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
2个月前
已完结
MYC Alterations in Diffuse Large B-Cell Lymphomas
2个月前
已完结
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
7个月前
已完结
皖公网安备34019202002308
